"TBSF" (20%) Human Albumin Solution

Country: Awstralja

Lingwa: Ingliż

Sors: Department of Health (Therapeutic Goods Administration)

Ingredjent attiv:

Albumin, Quantity: 200 g/L

Disponibbli minn:

CSL Behring Australia Pty Ltd

INN (Isem Internazzjonali):

Albumin

Għamla farmaċewtika:

Injection, solution

Kompożizzjoni:

Excipient Ingredients: octanoate; sodium

Rotta amministrattiva:

Intravenous

Unitajiet fil-pakkett:

50mL, 100mL

Klassi:

Medicine Listed (Export Only)

Tip ta 'preskrizzjoni:

(S1) This Schedule is intentionally blank

Indikazzjonijiet terapewtiċi:

Hypoproteinaemia in the acutely ill patient TBSF (20%) Human Albumin Solution is administered when there are existing or anticipated clinical problems or complications from reduced oncotic pressure, and/or as an adjunct to diuretic therapy. Shock. TBSF (20%) Human Albumin Solution may be used for the resuscitation of patients in shock due to acute loss of blood or plasma, but 4 - 5% human albumin is preferred when available. Burns. Extensive burns are followed by sequential shifts in the distribution of body water, salt and proteins resulting in hypovolaemic shock and circulatory failure.

Sommarju tal-prodott:

Visual Identification: Clear, slightly viscous almost colourless, yellow or green; Container Type: Vial; Container Life Time: 4 Years; Container Temperature: Store below 30 degrees Celsius

L-istatus ta 'awtorizzazzjoni:

Listed (Export Only)

Data ta 'l-awtorizzazzjoni:

2006-03-01